Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 9/2010

01.09.2010 | Original Article

Sociodemographics and Comorbidities Influence Decisions to Undergo Pancreatic Resection for Neoplastic Lesions

verfasst von: Charbel Sandroussi, Chantelle Brace, Erin D. Kennedy, Nancy N. Baxter, Steven Gallinger, Alice C. Wei

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 9/2010

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Pancreatic resection is being performed with increasing frequency and safety. Technical outcomes and long-term survival for neoplastic lesions are well reported; however, reasons why patients do not undergo surgery for potentially resectable lesions are not well understood. The aim of this study was to determine the factors contributing to the decision not to operate for resectable pancreatic neoplasms.

Methods

From 2004 to 2008, all patients with resectable pancreatic neoplasms at a single high-volume hepatopancreaticobiliary center were evaluated. The impact of patient factors, sociodemographics, medical comorbidities (Charlson combined comorbidity index (CCI) and ACCI), disease factors (tumor characteristics), and surgical factors (type of resection required) on the decision to undergo pancreatectomy were analyzed using univariate and multivariate binary logistic regression analysis.

Results

Three hundred seventy-five patients with resectable pancreatic lesions were identified. The median age was 62 years (21–93); 203 out of 375 (54.1%) were males. Fifty-five (14.7%) did not undergo resection. On univariate analysis, age (odds ratio (OR) 1.116, p < 0.001), non-English speaking background (NESB; OR 4.276, p = 0.001), tumor type (p = 0.001 increased for cystic neoplasms including intraductal papillary mucinous neoplasm), CCI score (OR 1.239, p = 0.001), and ACCI score (OR 1.433, p < 0.001) were associated with an increased risk of not undergoing resection. Gender, age, marital status, and urban residence were not predictive. On multivariate analysis, NESB (p = 0.018) and the ACCI (p = 0.002) remained predictive of not undergoing resection. The majority of patients did not undergo surgery because the patient declined in 25 out of 55 (45.5%), and resection was not offered in 15 out of 55 (27.3%). In the remainder, medical contraindications precluded surgery. Advanced age, tumor type, comorbidities (27.3%), age (21.8%), surgical risk (29.1%), frailty (18.2%), and uncertain diagnosis (5.5%) were cited as reasons for not proceeding with surgery.

Conclusion

Patients with a higher ACCI and those from a NESB are less likely to undergo surgery for resectable neoplastic lesions of the pancreas. These factors must be taken into consideration in the decision-making process when considering surgery for patients with pancreatic neoplasms. Novel strategies should be employed to optimize access to surgery for patients with resectable pancreatic neoplasms.
Literatur
1.
Zurück zum Zitat Azria D, Ychou M, Jacot W, et al. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin. Pancreas 2002; 25(4):360–5.CrossRefPubMed Azria D, Ychou M, Jacot W, et al. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin. Pancreas 2002; 25(4):360–5.CrossRefPubMed
2.
Zurück zum Zitat Lavu H, Mascaro AA, Grenda DR, et al. Margin positive pancreaticoduodenectomy is superior to palliative bypass in locally advanced pancreatic ductal adenocarcinoma. J Gastrointest Surg 2009; 13:1937–1946.CrossRefPubMed Lavu H, Mascaro AA, Grenda DR, et al. Margin positive pancreaticoduodenectomy is superior to palliative bypass in locally advanced pancreatic ductal adenocarcinoma. J Gastrointest Surg 2009; 13:1937–1946.CrossRefPubMed
3.
Zurück zum Zitat Okamoto A, Tsuruta K, Karasawa K, et al. Resection versus palliation: treatment of stage III and IVA carcinomas of the pancreas employing intraoperative radiation. World J Surg 2003; 27(5):599–605.CrossRefPubMed Okamoto A, Tsuruta K, Karasawa K, et al. Resection versus palliation: treatment of stage III and IVA carcinomas of the pancreas employing intraoperative radiation. World J Surg 2003; 27(5):599–605.CrossRefPubMed
4.
Zurück zum Zitat Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358(9293):1576–85.CrossRefPubMed Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358(9293):1576–85.CrossRefPubMed
5.
Zurück zum Zitat Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001; 234(6):758–68.CrossRefPubMed Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001; 234(6):758–68.CrossRefPubMed
6.
Zurück zum Zitat Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350(12):1200–10.CrossRefPubMed Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350(12):1200–10.CrossRefPubMed
7.
Zurück zum Zitat Ramacciato G, Mercantini P, Petrucciani N, et al. Does portal-superior mesenteric vein invasion still indicate irresectability for pancreatic carcinoma? Ann Surg Oncol 2009; 16(4):817–25.CrossRefPubMed Ramacciato G, Mercantini P, Petrucciani N, et al. Does portal-superior mesenteric vein invasion still indicate irresectability for pancreatic carcinoma? Ann Surg Oncol 2009; 16(4):817–25.CrossRefPubMed
8.
Zurück zum Zitat Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. Jama 2008; 299(9):1019–26.CrossRefPubMed Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. Jama 2008; 299(9):1019–26.CrossRefPubMed
9.
Zurück zum Zitat Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. Jama 1998; 280(20):1747–51.CrossRefPubMed Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. Jama 1998; 280(20):1747–51.CrossRefPubMed
10.
Zurück zum Zitat Glasgow RE, Jackson HH, Neumayer L, et al. Pancreatic resection in Veterans Affairs and selected university medical centers: results of the patient safety in surgery study. J Am Coll Surg 2007; 204(6):1252–60.CrossRefPubMed Glasgow RE, Jackson HH, Neumayer L, et al. Pancreatic resection in Veterans Affairs and selected university medical centers: results of the patient safety in surgery study. J Am Coll Surg 2007; 204(6):1252–60.CrossRefPubMed
11.
Zurück zum Zitat Glasgow RE, Mulvihill SJ. Hospital volume influences outcome in patients undergoing pancreatic resection for cancer. West J Med 1996; 165(5):294–300.PubMed Glasgow RE, Mulvihill SJ. Hospital volume influences outcome in patients undergoing pancreatic resection for cancer. West J Med 1996; 165(5):294–300.PubMed
12.
Zurück zum Zitat Balcom 4th JH, Rattner DW, Warshaw AL, et al. Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg 2001; 136(4):391–8.CrossRefPubMed Balcom 4th JH, Rattner DW, Warshaw AL, et al. Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg 2001; 136(4):391–8.CrossRefPubMed
13.
Zurück zum Zitat Lightner AM, Glasgow RE, Jordan TH, et al. Pancreatic resection in the elderly. J Am Coll Surg 2004; 198(5):697–706.CrossRefPubMed Lightner AM, Glasgow RE, Jordan TH, et al. Pancreatic resection in the elderly. J Am Coll Surg 2004; 198(5):697–706.CrossRefPubMed
14.
Zurück zum Zitat Petrowsky H, Clavien PA. Should we deny surgery for malignant hepato-pancreatico-biliary tumors to elderly patients? World J Surg 2005; 29(9):1093–100.CrossRefPubMed Petrowsky H, Clavien PA. Should we deny surgery for malignant hepato-pancreatico-biliary tumors to elderly patients? World J Surg 2005; 29(9):1093–100.CrossRefPubMed
15.
Zurück zum Zitat Tamijmarane A, Bhati CS, Mirza DF, et al. Application of Portsmouth modification of physiological and operative severity scoring system for enumeration of morbidity and mortality (P-POSSUM) in pancreatic surgery. World J Surg Oncol 2008; 6:39.CrossRefPubMed Tamijmarane A, Bhati CS, Mirza DF, et al. Application of Portsmouth modification of physiological and operative severity scoring system for enumeration of morbidity and mortality (P-POSSUM) in pancreatic surgery. World J Surg Oncol 2008; 6:39.CrossRefPubMed
16.
Zurück zum Zitat Ouellette JR, Small DG, Termuhlen PM. Evaluation of Charlson-Age Comorbidity Index as predictor of morbidity and mortality in patients with colorectal carcinoma. J Gastrointest Surg 2004; 8(8):1061–67.CrossRefPubMed Ouellette JR, Small DG, Termuhlen PM. Evaluation of Charlson-Age Comorbidity Index as predictor of morbidity and mortality in patients with colorectal carcinoma. J Gastrointest Surg 2004; 8(8):1061–67.CrossRefPubMed
17.
Zurück zum Zitat de Castro SM, Biere SS, Lagarde SM, et al. Validation of a nomogram for predicting survival after resection for adenocarcinoma of the pancreas. Br J Surg 2009; 96(4):417–23.CrossRefPubMed de Castro SM, Biere SS, Lagarde SM, et al. Validation of a nomogram for predicting survival after resection for adenocarcinoma of the pancreas. Br J Surg 2009; 96(4):417–23.CrossRefPubMed
18.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5):373–83.CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5):373–83.CrossRefPubMed
19.
Zurück zum Zitat Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47(11):1245–51.CrossRefPubMed Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47(11):1245–51.CrossRefPubMed
20.
Zurück zum Zitat O'Connor KM, Davis N, Lennon GM, et al. Can we avoid surgery in elderly patients with renal masses by using the Charlson comorbidity index? BJU Int 2008; 103:1492–1495.CrossRefPubMed O'Connor KM, Davis N, Lennon GM, et al. Can we avoid surgery in elderly patients with renal masses by using the Charlson comorbidity index? BJU Int 2008; 103:1492–1495.CrossRefPubMed
21.
Zurück zum Zitat Koppie TM, Serio AM, Vickers AJ, et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer 2008; 112(11):2384–92.CrossRefPubMed Koppie TM, Serio AM, Vickers AJ, et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer 2008; 112(11):2384–92.CrossRefPubMed
22.
Zurück zum Zitat Dalton SO, Schuz J, Engholm G, et al. Social inequality in incidence of and survival from cancer in a population-based study in Denmark, 1994–2003: Summary of findings. Eur J Cancer 2008; 44(14):2074–85.CrossRefPubMed Dalton SO, Schuz J, Engholm G, et al. Social inequality in incidence of and survival from cancer in a population-based study in Denmark, 1994–2003: Summary of findings. Eur J Cancer 2008; 44(14):2074–85.CrossRefPubMed
23.
Zurück zum Zitat Clegg LX, Li FP, Hankey BF, et al. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med 2002; 162(17):1985–93.CrossRefPubMed Clegg LX, Li FP, Hankey BF, et al. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med 2002; 162(17):1985–93.CrossRefPubMed
24.
Zurück zum Zitat Oliver MN. Access to prostate cancer care and implications for survival among minorities. J Urol 2009; 181(2):447–8.CrossRefPubMed Oliver MN. Access to prostate cancer care and implications for survival among minorities. J Urol 2009; 181(2):447–8.CrossRefPubMed
25.
Zurück zum Zitat Polite BN, Dignam JJ, Olopade OI. Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol 2006; 24(14):2179–87.CrossRefPubMed Polite BN, Dignam JJ, Olopade OI. Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol 2006; 24(14):2179–87.CrossRefPubMed
26.
Zurück zum Zitat D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 1996; 49(12):1429–33.CrossRefPubMed D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 1996; 49(12):1429–33.CrossRefPubMed
27.
Zurück zum Zitat Sundararajan V, Henderson T, Perry C, et al. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 2004; 57(12):1288–94.CrossRefPubMed Sundararajan V, Henderson T, Perry C, et al. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 2004; 57(12):1288–94.CrossRefPubMed
28.
Zurück zum Zitat Neoptolemos JP, Stocken DD, Tudur Smith C, et al. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer 2009; 100(2):246–50.CrossRefPubMed Neoptolemos JP, Stocken DD, Tudur Smith C, et al. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer 2009; 100(2):246–50.CrossRefPubMed
29.
Zurück zum Zitat Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006; 244(1):10–5.CrossRefPubMed Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006; 244(1):10–5.CrossRefPubMed
30.
Zurück zum Zitat Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer 2007; 110(6):1227–34.CrossRefPubMed Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer 2007; 110(6):1227–34.CrossRefPubMed
31.
Zurück zum Zitat Fernandez-Cruz L, Blanco L, Cosa R, Rendon H. Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors? World J Surg 2008; 32(5):904–17.CrossRefPubMed Fernandez-Cruz L, Blanco L, Cosa R, Rendon H. Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors? World J Surg 2008; 32(5):904–17.CrossRefPubMed
32.
Zurück zum Zitat Casadei R, Ricci C, Zanini N, et al. Laparoscopic distal pancreatectomy in non-malignant pancreatic tumors. Jop 2008; 9(1):71–3.PubMed Casadei R, Ricci C, Zanini N, et al. Laparoscopic distal pancreatectomy in non-malignant pancreatic tumors. Jop 2008; 9(1):71–3.PubMed
33.
Zurück zum Zitat Eom BW, Jang JY, Lee SE, et al. Clinical outcomes compared between laparoscopic and open distal pancreatectomy. Surg Endosc 2008; 22(5):1334–8.CrossRefPubMed Eom BW, Jang JY, Lee SE, et al. Clinical outcomes compared between laparoscopic and open distal pancreatectomy. Surg Endosc 2008; 22(5):1334–8.CrossRefPubMed
34.
Zurück zum Zitat Bilimoria KY, Bentrem DJ, Ko CY, et al. National failure to operate on early stage pancreatic cancer. Ann Surg 2007; 246(2):173–80.CrossRefPubMed Bilimoria KY, Bentrem DJ, Ko CY, et al. National failure to operate on early stage pancreatic cancer. Ann Surg 2007; 246(2):173–80.CrossRefPubMed
35.
Zurück zum Zitat Cress RD, Yin D, Clarke L, et al. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control 2006; 17(4):403–9.CrossRefPubMed Cress RD, Yin D, Clarke L, et al. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control 2006; 17(4):403–9.CrossRefPubMed
36.
Zurück zum Zitat Riall TS, Nealon WH, Goodwin JS, et al. Pancreatic cancer in the general population: improvements in survival over the last decade. J Gastrointest Surg 2006; 10(9):1212–23; discussion 1223–4.CrossRefPubMed Riall TS, Nealon WH, Goodwin JS, et al. Pancreatic cancer in the general population: improvements in survival over the last decade. J Gastrointest Surg 2006; 10(9):1212–23; discussion 1223–4.CrossRefPubMed
37.
Zurück zum Zitat Kondo K, Chijiiwa K, Funagayama M, et al. Hepatic resection is justified for elderly patients with hepatocellular carcinoma. World J Surg 2008; 32(10):2223–9.CrossRefPubMed Kondo K, Chijiiwa K, Funagayama M, et al. Hepatic resection is justified for elderly patients with hepatocellular carcinoma. World J Surg 2008; 32(10):2223–9.CrossRefPubMed
38.
Zurück zum Zitat Vickers SM, Kerby JD, Smoot TM, et al. Economics of pancreatoduodenectomy in the elderly. Surgery 1996; 120(4):620–5; discussion 625–6.CrossRefPubMed Vickers SM, Kerby JD, Smoot TM, et al. Economics of pancreatoduodenectomy in the elderly. Surgery 1996; 120(4):620–5; discussion 625–6.CrossRefPubMed
39.
Zurück zum Zitat Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006; 10(9):1199–1210; discussion 1210–1.CrossRefPubMed Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006; 10(9):1199–1210; discussion 1210–1.CrossRefPubMed
40.
Zurück zum Zitat Finlayson EV, Goodney PP, Birkmeyer JD. Hospital volume and operative mortality in cancer surgery: a national study. Arch Surg 2003; 138(7):721–5; discussion 726.CrossRefPubMed Finlayson EV, Goodney PP, Birkmeyer JD. Hospital volume and operative mortality in cancer surgery: a national study. Arch Surg 2003; 138(7):721–5; discussion 726.CrossRefPubMed
41.
Zurück zum Zitat Riall TS, Nealon WH, Goodwin JS, et al. Outcomes following pancreatic resection: variability among high-volume providers. Surgery 2008; 144(2):133–40.CrossRefPubMed Riall TS, Nealon WH, Goodwin JS, et al. Outcomes following pancreatic resection: variability among high-volume providers. Surgery 2008; 144(2):133–40.CrossRefPubMed
42.
Zurück zum Zitat Bilimoria KY, Talamonti MS, Sener SF, et al. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg 2008; 207(4):510–9.CrossRefPubMed Bilimoria KY, Talamonti MS, Sener SF, et al. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg 2008; 207(4):510–9.CrossRefPubMed
43.
Zurück zum Zitat Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 349(22):2117–27.CrossRefPubMed Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 349(22):2117–27.CrossRefPubMed
44.
Zurück zum Zitat Finlayson E, Fan Z, Birkmeyer JD. Outcomes in octogenarians undergoing high-risk cancer operation: a national study. J Am Coll Surg 2007; 205(6):729–34.CrossRefPubMed Finlayson E, Fan Z, Birkmeyer JD. Outcomes in octogenarians undergoing high-risk cancer operation: a national study. J Am Coll Surg 2007; 205(6):729–34.CrossRefPubMed
45.
Zurück zum Zitat Rothman MD, Van Ness PH, O'Leary JR, Fried TR. Refusal of medical and surgical interventions by older persons with advanced chronic disease. J Gen Intern Med 2007; 22(7):982–7.CrossRefPubMed Rothman MD, Van Ness PH, O'Leary JR, Fried TR. Refusal of medical and surgical interventions by older persons with advanced chronic disease. J Gen Intern Med 2007; 22(7):982–7.CrossRefPubMed
46.
Zurück zum Zitat Gulbinas A, Barauskas G, Pundzius J. Preoperative stratification of pancreas-related morbidity after the Whipple procedure. Int Surg 2004; 89(1):39–45.PubMed Gulbinas A, Barauskas G, Pundzius J. Preoperative stratification of pancreas-related morbidity after the Whipple procedure. Int Surg 2004; 89(1):39–45.PubMed
47.
Zurück zum Zitat Wang CY, Lin YS, Tzao C, et al. Comparison of Charlson comorbidity index and Kaplan–Feinstein index in patients with stage I lung cancer after surgical resection. Eur J Cardiothorac Surg 2007; 32(6):877–81.CrossRefPubMed Wang CY, Lin YS, Tzao C, et al. Comparison of Charlson comorbidity index and Kaplan–Feinstein index in patients with stage I lung cancer after surgical resection. Eur J Cardiothorac Surg 2007; 32(6):877–81.CrossRefPubMed
48.
Zurück zum Zitat Woodfield JC, Pettigrew RA, Plank LD, et al. Accuracy of the surgeons' clinical prediction of perioperative complications using a visual analog scale. World J Surg 2007; 31(10):1912–20.CrossRefPubMed Woodfield JC, Pettigrew RA, Plank LD, et al. Accuracy of the surgeons' clinical prediction of perioperative complications using a visual analog scale. World J Surg 2007; 31(10):1912–20.CrossRefPubMed
49.
Zurück zum Zitat Iversen LH, Norgaard M, Jacobsen J, et al. The impact of comorbidity on survival of Danish colorectal cancer patients from 1995 to 2006—a population-based cohort study. Dis Colon Rectum 2009; 52(1):71–8.PubMed Iversen LH, Norgaard M, Jacobsen J, et al. The impact of comorbidity on survival of Danish colorectal cancer patients from 1995 to 2006—a population-based cohort study. Dis Colon Rectum 2009; 52(1):71–8.PubMed
50.
Zurück zum Zitat Lubke T, Monig SP, Schneider PM, et al. Does Charlson-comorbidity index correlate with short-term outcome in patients with gastric cancer? Zentralbl Chir 2003; 128(11):970–6.CrossRefPubMed Lubke T, Monig SP, Schneider PM, et al. Does Charlson-comorbidity index correlate with short-term outcome in patients with gastric cancer? Zentralbl Chir 2003; 128(11):970–6.CrossRefPubMed
51.
Zurück zum Zitat Baastrup R, Sorensen M, Hansen J, et al. Social inequality and incidence of and survival from cancers of the oesophagus, stomach and pancreas in a population-based study in Denmark, 1994-2003. Eur J Cancer 2008; 44(14):1962–77.CrossRefPubMed Baastrup R, Sorensen M, Hansen J, et al. Social inequality and incidence of and survival from cancers of the oesophagus, stomach and pancreas in a population-based study in Denmark, 1994-2003. Eur J Cancer 2008; 44(14):1962–77.CrossRefPubMed
52.
Zurück zum Zitat Merrill RM, Merrill AV, Mayer LS. Factors associated with no surgery or radiation therapy for invasive cervical cancer in Black and White women. Ethn Dis 2000; 10(2):248–56.PubMed Merrill RM, Merrill AV, Mayer LS. Factors associated with no surgery or radiation therapy for invasive cervical cancer in Black and White women. Ethn Dis 2000; 10(2):248–56.PubMed
53.
Zurück zum Zitat Dignan M, Michielutte R, Sharp P, et al. The role of focus groups in health education for cervical cancer among minority women. J Community Health 1990; 15(6):369–75.CrossRefPubMed Dignan M, Michielutte R, Sharp P, et al. The role of focus groups in health education for cervical cancer among minority women. J Community Health 1990; 15(6):369–75.CrossRefPubMed
54.
Zurück zum Zitat Thomas V, Richardson A, Saleem T, et al. The efficacy of bilingual health advocacy in ethnic minority patients with cancer. Nurs Stand 2000; 14(26):32–3.PubMed Thomas V, Richardson A, Saleem T, et al. The efficacy of bilingual health advocacy in ethnic minority patients with cancer. Nurs Stand 2000; 14(26):32–3.PubMed
55.
Zurück zum Zitat Alcaraz KI, Kreuter MW, Davis KL, et al. On linkages: increasing awareness of and interest in public health and cancer control careers among minority middle school students. Public Health Rep 2008; 123(4):533–9.PubMed Alcaraz KI, Kreuter MW, Davis KL, et al. On linkages: increasing awareness of and interest in public health and cancer control careers among minority middle school students. Public Health Rep 2008; 123(4):533–9.PubMed
56.
Zurück zum Zitat Gany FM, Herrera AP, Avallone M, Changrani J. Attitudes, knowledge, and health-seeking behaviors of five immigrant minority communities in the prevention and screening of cancer: a focus group approach. Ethn Health 2006; 11(1):19–39.CrossRefPubMed Gany FM, Herrera AP, Avallone M, Changrani J. Attitudes, knowledge, and health-seeking behaviors of five immigrant minority communities in the prevention and screening of cancer: a focus group approach. Ethn Health 2006; 11(1):19–39.CrossRefPubMed
57.
Zurück zum Zitat Hawthorne K, Robles Y, Cannings-John R, Edwards AG. Culturally appropriate health education for type 2 diabetes mellitus in ethnic minority groups. Cochrane Database Syst Rev 2008(3):CD006424. Hawthorne K, Robles Y, Cannings-John R, Edwards AG. Culturally appropriate health education for type 2 diabetes mellitus in ethnic minority groups. Cochrane Database Syst Rev 2008(3):CD006424.
Metadaten
Titel
Sociodemographics and Comorbidities Influence Decisions to Undergo Pancreatic Resection for Neoplastic Lesions
verfasst von
Charbel Sandroussi
Chantelle Brace
Erin D. Kennedy
Nancy N. Baxter
Steven Gallinger
Alice C. Wei
Publikationsdatum
01.09.2010
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 9/2010
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-010-1255-2

Weitere Artikel der Ausgabe 9/2010

Journal of Gastrointestinal Surgery 9/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.